Holen Sie sich die Stockscreener-App
10.46
1.04%
-0.09
Schlusskurs vom Vortag:
$10.55
Offen:
$11
24-Stunden-Volumen:
907.05K
Relative Volume:
0.37
Marktkapitalisierung:
$1.87B
Einnahmen:
$15.36M
Nettoeinkommen (Verlust:
$-276.48M
KGV:
-6.4852
EPS:
-1.6129
Netto-Cashflow:
$-235.87M
1W Leistung:
+5.56%
1M Leistung:
+16.91%
6M Leistung:
+161.65%
1J Leistung:
+206.16%
1-Tages-Spanne:
$10.32
$11.49
1-Wochen-Bereich:
$9.6101
$11.49
52-Wochen-Spanne:
$1.775
$11.49
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
10.44 | 1.89B | 15.36M | -276.48M | -235.87M | -1.6129 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.38 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.33 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.43 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-04-17 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Guggenheim Raises Price Target for Relay Therapeutics (RLAY) to $22 | RLAY Stock News - GuruFocus
Can Relay Therapeutics Inc expand into new markets2026 Market Sentiment & Growth Focused Stock Reports - baoquankhu1.vn
Relay Therapeutics Files Amended and Restated Bylaws with SEC – Key Company Information and Filing Details - Minichart
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Thomas Catinazzo Sells Shares of Relay Therapeutics Inc (RLAY) - GuruFocus
Relay Therapeutics Updates Bylaws on Federal Securities Litigation - TipRanks
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Zovegalisib Milestones To Shape The Future Of Relay Therapeutics - RTTNews
Investment Review: Can Relay Therapeutics Inc sustain its profitability2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
A Look At Relay Therapeutics (RLAY) Valuation After Earnings Update And New Shelf Registration - Sahm
Relay Therapeutics Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Should I add Relay Therapeutics Inc stock to my portfolio2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst - Seeking Alpha
Relay Therapeutics Stock Price Rises 6% - National Today
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6%Should You Buy? - MarketBeat
Why Relay Therapeutics (RLAY) Is Up 14.8% After 2025 Beat, FDA Breakthrough Win for Zovegalisib - Sahm
Relay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Decrease in Short Interest - MarketBeat
Citizens reiterates Relay Therapeutics stock rating ahead of data By Investing.com - Investing.com Canada
Aug Levels: Is Relay Therapeutics Inc stock showing strong momentum2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status - Investing.com Nigeria
RLAYRelay Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Relay Therapeutics’ Promising Path with FDA Approvals and Revenue Growth - timothysykes.com
Bank Watch: What is the earnings history of Relay Therapeutics IncWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - Sahm
Relay Therapeutics Surges After Breakthrough Designation for Breast Cancer Treatment - StocksToTrade
Relay Therapeutics’ Q4 Financial Performance Surges Amid Breakthrough Recognition - timothysykes.com
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest - Yahoo Finance
Relay Therapeutics (RLAY) Losses Of US$276.5 Million Test Bullish Revenue Growth Narrative - simplywall.st
Relay Therapeutics stock hits 52-week high at 9.64 USD By Investing.com - Investing.com Australia
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million - AOL.com
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 61.57% Potential Upside in Precision Medicine - DirectorsTalk Interviews
RLAY: Wells Fargo Raises Price Target to $15, Maintains Overweig - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $15.00 - MarketBeat
RLAY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Relay Therapeutics Shares Jump 19% On Earnings And Pipeline Progress - Nasdaq
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High on Strong Earnings - MarketBeat
Relay Therapeutics stock hits 52-week high at 9.64 USD - Investing.com
A Look At Relay Therapeutics (RLAY) Valuation As Shares Rebound And Trade Below Analyst Targets - simplywall.st
Decoding Relay Therapeutics Inc (RLAY): A Strategic SWOT Insight - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Announces Quarterly Earnings Results - MarketBeat
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - Investing News Network
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Relay Therapeutics (RLAY) Surpasses Q4 Revenue Estimates, Eyes C - GuruFocus
Relay Therapeutics Q4 Loss Narrows, Revenue Rises; Cash Runway Into 2029 - marketscreener.com
Earnings Flash (RLAY) Relay Therapeutics Posts Q4 Loss Per Share $0.32, vs. FactSet Est of $0.40 Loss - marketscreener.com
Relay Therapeutics beats Q4 revenue expectations - TradingView
Relay Therapeutics Q4 Earnings Assessment - Benzinga
Relay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q4 Revenue $7.0M, vs. FactSet Est of $5.0M - marketscreener.com
Relay Therapeutics (NASDAQ: RLAY) narrows 2025 loss and sets major 2026 zovegalisib data milestones - Stock Titan
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):